Royalty Pharma Plc (RPRX)
Royalty Pharma Plc (RPRX) carries a ŷRobot AI score of 73 out of 100. The model's fair value estimate is $71.76, 3.5% above the last close of $69.31. The chart signal reads Sell.
| Metric | RPRX |
|---|---|
| AI score | 73 / 100 |
| Chart signal | Sell |
| Fair value estimate | $71.76 |
| Upside to fair value | 3.5% |
| Previous close | $69.31 |
| P/E | 44.16 |
| Price / sales | 11.86 |
| Market cap | $40.26B |
| EPS | 1.53 |
| Revenue growth | 1.4% |
| 1-year price change | 28.3% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about RPRX
Is RPRX overvalued or undervalued right now?
As of Nov 6, 2026, ŷRobot's fair-value model estimates Royalty Pharma Plc (RPRX) at $71.76 against a last close of $69.31, implying 3.5% upside to the model's estimate.
Is RPRX's chart signal bullish or bearish?
The chart-signal model classifies RPRX as Neutral as of Nov 13, 2026, with a signal score of -0.11 on a -1 to 1 scale.
What is RPRX's ŷRobot AI score?
RPRX scores 73 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is RPRX stock expensive on P/E and P/S?
RPRX trades at 44.2 times earnings and 11.9 times sales as of Nov 13, 2026.
What does RPRX's seasonal forecast show?
ŷRobot's seasonal forecast curve for RPRX reads +2.5% at 30 days, +10.5% at 90 days, and +28.3% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is RPRX growing?
Royalty Pharma Plc's revenue growth is +1.4% and free-cash-flow growth is -5.7% on the latest reported figures.
RPRX chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.